Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Up 128.9% in December

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 35,432 shares, a growth of 128.9% from the December 15th total of 15,480 shares. Based on an average trading volume of 25,466 shares, the short-interest ratio is presently 1.4 days. Currently, 2.8% of the shares of the company are short sold. Currently, 2.8% of the shares of the company are short sold. Based on an average trading volume of 25,466 shares, the short-interest ratio is presently 1.4 days.

Sonoma Pharmaceuticals Stock Down 2.6%

Shares of Sonoma Pharmaceuticals stock opened at $3.34 on Wednesday. Sonoma Pharmaceuticals has a 12-month low of $1.75 and a 12-month high of $6.92. The company has a market capitalization of $5.68 million, a price-to-earnings ratio of -1.53 and a beta of 1.61. The firm’s 50-day moving average price is $3.53 and its two-hundred day moving average price is $3.79.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.18. Sonoma Pharmaceuticals had a negative net margin of 20.57% and a negative return on equity of 45.46%. On average, sell-side analysts expect that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on SNOA. Wall Street Zen upgraded shares of Sonoma Pharmaceuticals to a “hold” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management purchased a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned approximately 2.06% of Sonoma Pharmaceuticals as of its most recent filing with the SEC. 1.95% of the stock is currently owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.